Vafseo Approved for Anemia Due to CKD in Patients on Dialysis
Vafseo is an oral reversible inhibitor of hypoxia-inducible factor (HIF)-prolyl-4-hydroxylases (PH)1, PH2, and PH3.
Source: renalandurologynews.com
📰 Boxed Warning News
Page 4 - Boxed Warning News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.
UPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING
/PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be participating in the 2024 American Academy of Neurology (AAN)...
United States Maple Grove Prnewswire Upsher Smith Laboratories American Academy Of Neurology Annual Meeting Upsher Smith Laboratories Program At Booth
Source: prnewswire.com
Marius Pharmaceuticals Announces Final Published Phase 3 Data from MRS-TU-2019EXT Studying the Safety and Efficacy of FDA-Approved KYZATREX® (testosterone undecanoate) CII Capsules
/PRNewswire/ -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced...
Source: prnewswire.com
FDA Expands Enhertu Indication to HER2-Positive Solid Tumors
The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.
United States University Of Texas Md Anderson Cancer Center Drug Administration Daiichi Sankyo Inc Daiichi Sankyo Cancer Center
Source: medscape.com
FDA Approves Enhertu for Some With HER2-Positive Solid Tumors
Enhertu has been approved by the FDA for certain patients with unresectable or metastatic HER2-positive solid tumors.
Source: curetoday.com
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...
Source: marketscreener.com
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...
United Kingdom United States Ben Shamsian Lytham Company Compensation Committee Compensation Committee Company Or Delcath
Source: marketscreener.com
Vigpoder for Oral Solution Now Available for Refractory CPS, Infantile Spasms
The prescribing information for Vigpoder carries a Boxed Warning associated with a risk for permanent vision loss.
Michael Smith Pyros Pharmaceuticals Boxed Warning Vigabatrin Risk Evaluation Mitigation Strategy Pyros Total
Source: empr.com
Vafseo Approved for Anemia Due to CKD in Patients on Dialysis
The FDA has approved vadadustat for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least 3 months.
Source: endocrinologyadvisor.com
FDA approves J&J's OPSYNVI for pulmonary arterial hypertension patients
In a significant milestone for pulmonary arterial hypertension (PAH) patients, Johnson & Johnson has announced the approval of OPSYNVI.
Kelly Chin Drug Administration Pulmonary Hypertension Program World Health Organization Ut Southwestern Medical Center Medical Center
Source: outsourcing-pharma.com